Outcomes of fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms in patients with heritable thoracic aortic diseases

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Lucas Ribé MD , Lucas Ruiter Kanamori MD , Bruno P. Schmid MD , Thanila A. Macedo MD , Bernardo C. Mendes MD , Steven Maximus MD , Ying Huang MD, PhD , Felipe Nasser MD, PhD , Gustavo S. Oderich MD
{"title":"Outcomes of fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms in patients with heritable thoracic aortic diseases","authors":"Lucas Ribé MD ,&nbsp;Lucas Ruiter Kanamori MD ,&nbsp;Bruno P. Schmid MD ,&nbsp;Thanila A. Macedo MD ,&nbsp;Bernardo C. Mendes MD ,&nbsp;Steven Maximus MD ,&nbsp;Ying Huang MD, PhD ,&nbsp;Felipe Nasser MD, PhD ,&nbsp;Gustavo S. Oderich MD","doi":"10.1016/j.xjtc.2025.04.025","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Open surgical repair is the first-line treatment for patients with complex aortic aneurysms and heritable thoracic aortic diseases (HTADs). Fenestrated-branched endovascular aortic repair (FB-EVAR) has been used selectively in higher-risk patients. This study assessed early- and midterm outcomes of FB-EVAR for complex aortic aneurysms in patients with HTADs.</div></div><div><h3>Methods</h3><div>We reviewed clinical data, imaging, and outcomes of consecutive patients treated by FB-EVAR for complex abdominal and thoracoabdominal aneurysms from April 2007 to June 2024. Patients with confirmed Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, or <em>ACTA2</em> mutation were included. End points included 30-day mortality and major adverse events, cumulative incidence of aortic-related mortality, aortic aneurysm rupture, and secondary interventions.</div></div><div><h3>Results</h3><div>Among 850 patients (median age, 58 years; interquartile range, 49-70 years; 8 [53%] men) treated by FB-EVAR for complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms, 15 (1.8%) had confirmed HTADs. Technical success was achieved with no early mortality in all patients. Early outcomes showed no cerebrovascular or major cardiac events. One patient developed delayed paraparesis with complete recovery. Median follow-up was 20 months (interquartile range, 13-34 months) with no aortic-related mortality and aortic aneurysm rupture. One patient developed a late retrograde dissection treated by thoracic endovascular aortic repair. Patient survival and cumulative incidence of secondary interventions at 1 year were 93% ± 16% and 10.0% (95% CI, 0.0%-26.8%), respectively.</div></div><div><h3>Conclusions</h3><div>FB-EVAR in select patients with a confirmed diagnosis of HTADs was associated with high technical success and no early mortality. Midterm outcomes revealed no aortic-related mortality or aortic aneurysm rupture, but 1 in 3 patients required secondary interventions, highlighting the importance of continuous surveillance in this population.</div></div>","PeriodicalId":53413,"journal":{"name":"JTCVS Techniques","volume":"32 ","pages":"Pages 10-19"},"PeriodicalIF":1.9000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTCVS Techniques","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666250725001725","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Open surgical repair is the first-line treatment for patients with complex aortic aneurysms and heritable thoracic aortic diseases (HTADs). Fenestrated-branched endovascular aortic repair (FB-EVAR) has been used selectively in higher-risk patients. This study assessed early- and midterm outcomes of FB-EVAR for complex aortic aneurysms in patients with HTADs.

Methods

We reviewed clinical data, imaging, and outcomes of consecutive patients treated by FB-EVAR for complex abdominal and thoracoabdominal aneurysms from April 2007 to June 2024. Patients with confirmed Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, or ACTA2 mutation were included. End points included 30-day mortality and major adverse events, cumulative incidence of aortic-related mortality, aortic aneurysm rupture, and secondary interventions.

Results

Among 850 patients (median age, 58 years; interquartile range, 49-70 years; 8 [53%] men) treated by FB-EVAR for complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms, 15 (1.8%) had confirmed HTADs. Technical success was achieved with no early mortality in all patients. Early outcomes showed no cerebrovascular or major cardiac events. One patient developed delayed paraparesis with complete recovery. Median follow-up was 20 months (interquartile range, 13-34 months) with no aortic-related mortality and aortic aneurysm rupture. One patient developed a late retrograde dissection treated by thoracic endovascular aortic repair. Patient survival and cumulative incidence of secondary interventions at 1 year were 93% ± 16% and 10.0% (95% CI, 0.0%-26.8%), respectively.

Conclusions

FB-EVAR in select patients with a confirmed diagnosis of HTADs was associated with high technical success and no early mortality. Midterm outcomes revealed no aortic-related mortality or aortic aneurysm rupture, but 1 in 3 patients required secondary interventions, highlighting the importance of continuous surveillance in this population.
遗传性胸主动脉疾病患者胸腹主动脉瘤开窗支腔内修复术的疗效
目的开放性手术修复是复杂性主动脉瘤和遗传性胸主动脉疾病(HTADs)患者的一线治疗方法。开窗分支血管内主动脉修复术(FB-EVAR)已被选择性地用于高危患者。本研究评估了HTADs患者复杂主动脉瘤FB-EVAR的早期和中期预后。方法回顾2007年4月至2024年6月连续行FB-EVAR治疗复杂腹、胸腹动脉瘤患者的临床资料、影像学和预后。确诊为马凡综合征、Loeys-Dietz综合征、血管性ehers - danlos综合征或ACTA2突变的患者被纳入研究。终点包括30天死亡率和主要不良事件、主动脉相关死亡率的累积发生率、主动脉瘤破裂和二次干预。结果850例患者中位年龄58岁;四分位数范围,49-70年;8例(53%)男性)接受FB-EVAR治疗复杂腹主动脉瘤和胸腹主动脉瘤,15例(1.8%)确诊HTADs。技术上的成功使所有患者无早期死亡。早期结果显示无脑血管或主要心脏事件。1例患者出现迟发性截瘫,但完全恢复。中位随访时间为20个月(四分位数间距13-34个月),无主动脉相关死亡和主动脉瘤破裂。1例患者经胸血管内主动脉修复术后发生晚期逆行夹层。患者1年生存率和二次干预累积发生率分别为93%±16%和10.0% (95% CI, 0.0%-26.8%)。结论在确诊为HTADs的患者中,sfb - evar与高技术成功率和无早期死亡率相关。中期结果显示无主动脉相关死亡或主动脉瘤破裂,但三分之一的患者需要二次干预,强调了在该人群中持续监测的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JTCVS Techniques
JTCVS Techniques Medicine-Surgery
CiteScore
1.60
自引率
6.20%
发文量
311
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信